T1	Participants 178 269	More than 50% of patients with Crohn's disease become either steroid resistant or dependent
T2	Participants 518 602	Patients with steroid-dependent Crohn's disease (n = 271) were enrolled in a 36-week
T3	Participants 926 950	Patients were randomized
T4	Participants 1083 1164	The primary efficacy endpoint was the percentage of patients with steroid sparing
T5	Participants 1509 1603	CDP571 was ineffective for sparing steroids in patients with steroid-dependent Crohn's disease
